Published since 1959, International Review of Neurobiology is a well-known series appealing to neuroscientists, clinicians, psychologists, physiologists, and pharmacologists. Led by an internationally renowned editorial board, this important serial publishes both eclectic volumes made up of timely reviews and thematic volumes that focus on recent progress in a specific area of neurobiology research.
This volume is a collection of articles covering recent advances in the field of neurobiology. Topics covered include chromosome 22 deletion syndrome and schizophrenia; characterization of proteome of human cerebrospinal fluid; hormonal pathways regulating intermale and interfemale aggression; neuronal gap junctions; effects of genes and stress on the neurobiology of depression; quantitative imaging with teh MicroPET small-animal PET tomograph; understanding myelination through studying its evolution.
Recenzijas
Praise for the Series: "A valuable addition to any college library as current reference material for advanced undergraduates, graduate students, and professional scientists." --Choice
Chromosome 22 Deletion Syndrome and Schizophrenia.
Characterization of Proteome of Human Cerebrospinal Fluid.
Hormonal Pathways Regulating Intermale and Interfemale Aggression.
Neuronal Gap Junctions: Expression, Function, and Implications for Behavior.
Effects of Genes and Stress on the Neurobiology of Depression.
Quantitative Imaging with the MicroPET Small-Animal PET Tomograph.
Understanding Myelination through Studying its Evolution.
Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinsons disease. He has spent the major part of his career at Kings College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of Kings College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders.
Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinsons disease patient-carer groups across the UK.
